14-month data show treatment with setrusumab resulted in a large, sustained 67% reduction in annualized fracture rate and persistent median annualized fracture...
SAN DIEGO, June 12, 2024 /PRNewswire/ -- Alida Biosciences (AlidaBio), an innovator in epigenomic research tools, proudly announces the successful completion...
VANCOUVER, BC / ACCESSWIRE / June 12, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), a leading biopharmaceutical...
SAN DIEGO, CA / ACCESSWIRE / June 11, 2024 / For those afflicted by substance abuse and mental illness, it's...
NEW YORK, June 11, 2024 /PRNewswire/ -- A computer program based on data from nearly a half-million tissue images and...
Latest version includes a prebuilt pangenome capturing more genetic diversity, reducing ancestry bias, and improving accuracy SAN DIEGO, June 11,...
New technology will enhance patient experience at Texas Oncology locations by reducing administrative burden for clinicians SAN FRANCISCO, June 11,...
Avenda Health's study, published in The Journal of Urology, solidifies the power of AI in oncology as a viable and...
The combined team will support Reveal's mission to unleash the full potential of AI technology for healthcare and life sciences...
Data-centric organizations in healthcare, financial, and travel services trust Scality RING as the foundation for AI-powered data lakes SAN FRANCISCO, June...
PathAI remains an independent company, focused on developing innovative AI and digital pathology solutions SECAUCUS, N.J. and BOSTON, June 11,...
2,300 patients in trial enrolled ahead of schedule12-month follow up period underway, with topline data anticipated in 2H 2025Trial designed...
Eight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 months At the highest NGC-Cap dose,...
AGOURA HILLS, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its CEO- Dr. Vuong Trieu...
NEEDHAM, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage...
Publication Highlights Activity of the Combination of TRC102 and Temodar (Temozolomide) in Patients who Progressed Following Initial Treatment with Surgical...
Company files expansive intellectual property protection for “Membrane Protein Factory” to produce purified and biologically active membrane proteins for drug...
New sponsored testing program leverages Myriad’s MyChoice Tests for patients with high-grade serous ovarian cancerSALT LAKE CITY, June 11, 2024...
- Chief Scientific Officer Dr. Newman to present initial clinical data that further validates Company’s “Pulse-Prime” hypothesis - Dr. Newman...
PARSORTIX SYSTEM AND ASSAYS BEING SHOWCASED AT THE 2024 ANNUAL CONGRESS OF THE EUROPEAN ASSOCIATION FOR CANCER RESEARCHANGLE presenting two...